[CIDP Refractory to Three Types of Mainstay Treatments: Appropriate Induction Therapy and Evaluation of Therapeutic Effect].

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disease with a heterogeneous pathology. The responsiveness to mainstay treatment differs depending on the type of CIDP. The treatment strategy is determined based on the type of CIDP, characteristics of the therapeutic agents and treatment methods, and patient background. For CIDPs that do not respond to the mainstay treatment, it is necessary to review whether the induction treatment was properly performed and whether the therapeutic effect was properly evaluated using objective indicators. In particular, treatment-resistant multifocal CIDP and distal CIDP require careful differential diagnoses. Intervention trials using rituximab and anti-neonatal Fcγ receptor monoclonal antibodies are underway, and it is expected that clear treatment guidelines will soon be developed for refractory CIDP.